Rosacea
Conditions
Interventions
Transcranial magnetic stimulation group:Transcranial magnetic stimulation+ Peripheral pseudo-stimulation
Peripheral magnetic stimulation group:Peripheral magnetic stimulation+ Transcranial pseudo-stimulation
Transcranial combined peripheral magnetic stimulation group:Transcranial combined peripheral magnetic stimulation
Sponsors
Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Definition of refractory rosacea: after 12 weeks (or more) oral conventional drugs such as doxycycline, with or without other treatments (such as topical drugs/IPL treatment), treatment resistance (erythema did not decrease by 1 grade or erythema greater than or equal to 3 degrees or flushing and other symptoms affecting the quality of life (DLQI moderate and above)) patients, or frequent relapse during 12 weeks of treatment; (2) voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: (1) Age 65 years; (2) Pregnant and lactating women and recent pregnancy plans. (3) Rose acne patients with nasal hyperplasia and hypertrophy; (4) Patients with moderate to severe systemic diseases such as liver, kidney, lung or blood; (5) Unstable physical diseases, including glaucoma, retinal detachment; severe cerebral hemorrhage, traumatic brain injury, tumor, infection and other diseases that may induce frequency response; acute massive cerebral infarction, multiple intracranial aneurysms; severe cardiovascular disease, especially cardiac pacemakers, cardiac stent installers or recent heart attacks; (6) abuse or dependence on alcohol and drugs in the past 3 months; (7) history of mental illness, including history of epilepsy, EEG suggests epileptiform changes; (8) taking drugs that may lower the seizure threshold; taking antidepressant drugs; previous or simultaneous use of electrobody therapy, vagus nerve stimulation or magnetic stimulation for other diseases. (9) Metal foreign bodies within 30 cm of the treatment site, such as cochlear implants, built-in pulse generators, aneurysm clips, stents, etc.; (10) Patients who have been treated with topical therapy within the past two weeks or systemic therapy with common drugs within 4 weeks or isotretinoin within 3 months. (11) Facial manifestations associated with other facial skin diseases (such as seborrheic dermatitis, eczema, etc.) or other diseases (such as dermatomyositis, systemic lupus erythematosus); (12) Patients who are expected to be unable to adhere to follow-up. (13) Participated in any clinical trial within one month. (14) Other conditions that the investigator considers not eligible for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rosacea Clinical Symptom Severity Assessment (Physician Assessment);Rating of existing skin lesions (physician evaluation);Rosacea Clinical Symptom Severity Assessment (Patient Assessment); | — |
Secondary
| Measure | Time frame |
|---|---|
| Paroxysmal flushing (patient evaluation);Skin Life Quality Index (DLQI) Questionnaire;Anxiety and depression (patient evaluation); | — |
Countries
China
Contacts
Public ContactBen Wang
Xiangya Hospital Central South University
Outcome results
None listed